跳至主要内容
临床试验/PER-062-02
PER-062-02已完成未知

A RANDOMIZED, DOUBLE-BLIND, MULTICENTRIC STUDY OF ZOLEDRONIC ACID (4 MG AND 8 MG) ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH RECIDIVAL OR REFRACTORY HYPERCALCEMIA, INDUCED BY NEOPLASIA.

OVARTIS BIOSCIENSES PERU S.A.,0 个研究点目标入组 0 人开始时间: 2002年10月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients who have signed the informed consent. When the patient is not able to sign, a legal representative may do so instead.
  • Patients> 18 years of age.
  • Patients with a diagnosis of cancer confirmed by histology or cytology.

排除标准

  • Pregnant patients. All patients with pregnancy potential must have a negative pregnancy test before the infusion of the study drug.
  • Patients with hyperparathyroidism, vitamin D intoxication, milk-alkaline syndrome, sarcoidosis or other granulomatous disease, adrenal insufficiency or multiple endocrine neoplasia syndromes.
  • Patients treated with bisphosphonates for other reasons than the TIH within 30 days prior to Visit 1.
  • Patients treated with calcitonin within 72 hours prior to Visit 1.

研究者

发起方
OVARTIS BIOSCIENSES PERU S.A.,

相似试验